$ALNY · ALNYLAM PHARMACEUTICALS, INC.
Alnylam filed an 8-K disclosing two items: a board-authorized $1.0 billion common stock repurchase program (the "2026 Repurchase Program") and the December 2026 departure of EVP and Chief Commercialization Officer Tolga Tanguler. The company anticipates repurchasing roughly $500 million by end of 2026 and the remainder during 2027, with no expiration date and full discretion to modify or suspend. Tanguler and the company intend to enter a written separation agreement by his separation date.
- Board authorized up to $1.0 billion in common stock repurchases under the 2026 Repurchase Program.
- Company expects ~$500 million of buybacks by end of 2026 and the balance during 2027.
- Program has no expiration date and may be modified, suspended, or discontinued at any time.
- CCO Tolga Tanguler will depart in December 2026; a written separation agreement is pending.
- Repurchases may occur via open market, 10b5-1 plans, or privately negotiated transactions.
Extended-hours last trade of $168.00 is +4.30% vs the $161.08 regular close, suggesting a positive initial reaction to the buyback authorization.
A $1.0 billion buyback signals capital-return confidence, though the concurrent CCO departure adds a leadership-transition watch item.
_Not applicable._
The buyback is discretionary and may be suspended or discontinued; the separation agreement with Tanguler has not yet been finalized.